Last reviewed · How we verify
Albuterol sulfate (ABS)
Albuterol sulfate is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation.
Albuterol sulfate is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation. Used for Asthma (acute bronchospasm relief and maintenance), Chronic obstructive pulmonary disease (COPD) (acute bronchospasm relief and maintenance), Exercise-induced bronchoconstriction prevention.
At a glance
| Generic name | Albuterol sulfate (ABS) |
|---|---|
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Drug class | Beta-2 adrenergic agonist (short-acting) |
| Target | Beta-2 adrenergic receptor (ADRB2) |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Albuterol activates beta-2 adrenergic receptors on bronchial smooth muscle, triggering a cascade that increases intracellular cAMP and leads to smooth muscle relaxation. This results in rapid airway dilation and improved airflow, providing symptomatic relief of bronchoconstriction. It is commonly used as a rescue medication for acute bronchospasm and as a maintenance therapy in obstructive airway diseases.
Approved indications
- Asthma (acute bronchospasm relief and maintenance)
- Chronic obstructive pulmonary disease (COPD) (acute bronchospasm relief and maintenance)
- Exercise-induced bronchoconstriction prevention
Common side effects
- Tremor
- Headache
- Nervousness/anxiety
- Palpitations
- Muscle cramps
- Tachycardia
Key clinical trials
- A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma (PHASE3)
- Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old (PHASE1)
- Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Albuterol sulfate (ABS) CI brief — competitive landscape report
- Albuterol sulfate (ABS) updates RSS · CI watch RSS
- Teva Branded Pharmaceutical Products R&D, Inc. portfolio CI